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Abstract 
In the last years, change in multiple sclerosis (MS) therapeutic scenario has highlighted the need for an 
improved doctor-patient communication in advance of treatment initiation in order to allow patient’s 
empowerment in the decision-making process. 
 
Aims 
The aims of our project were to review the strategies used by ItalianMS specialists to inform patients 
about treatment options and to design a multicentre shared document that homogenizes the information 




The new resource, obtained by consensus among 31 neurologists from 27MS Centres in Italy with the 
supervision of a medicolegal advisor, received the aegis of Italian Neurological Society (SIN) and 
constitutes a step toward a standardized decision process around DMTs in MS. 
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Background 
Over the last 10 years, multiple sclerosis (MS) therapeutic scenario has rapidly evolved with the 
introduction of new highly effective, but more risky disease-modifying treatments (DMTs). This change 
has increased the complexity of patient’s monitoring and has highlighted the need for an improved 
doctor-patient communication in advance of treatment initiation [1–3]. 
The choice of the “best” DMT for every single person with MS (PWMS) must be the resultant of a shared 
analysis of both the specific clinical, biological and MRI prognostic factors of the diseases and the DMT 
characteristics, side effects and potential risks. Data concerning risks and side effects derives not only 
from randomized clinical trials (RCTs), obtained in relatively small cohorts of patients with a relatively 
short follow-up period, but also from active pharmacovigilance and real-world post-marketing 
observations. A patient-centred care requires, indeed, a greater attention on communication between 
PWMS and physicians about treatment options, as this allows patient’s empowerment in the decision-
making process, sets correct patient’s expectations, prioritizes his needs and ultimately improves 
adherence and active participation to the treatment plan [4]. For these reasons, the Italian legislation 
(DLgs 219/-December 2017) states the mandatory nature of informed consent on care related decisions 
in clinical practice and requires the proofs of treatment consent (acceptance or denial) to be stored in the 
patient’s clinical records. 
 
Furthermore, an active engagement of PWMS could in-crease their knowledge of the treatments, 
including the longitudinal clinical measure requested to monitor and prevent long-term treatment side 
effects. Different tools (including educational programs, information aids and decision aids) have been 
developed all over the world in order to meet the information needs of PWMS [5, 6]. However, the 
possibility of sharing written information about DMTs among different MS centres is extremely 
challenging. Standardising the information would support PWMS who need to move from one centre to 
another and who, often in virtual community, share DMTs related information and might help clinicians 
in their clinical practice. 
 
The aims of our project were to review the strategies used by Italian MS specialists to inform PWMS 
about treatment options and to design a multicentre shared document that homogenizes the information 
about MS DMTs and the procedure of taking informed consent in clinical practice. 
 
Methods 
Thirty-one neurologists (age range, 33–57 years old), representative of 27 tertiary Italian MS Centres and 
a medico-legal advisor expert in communication and procedure of consent, participated in the project. 
The 27 MS centres are representative of different geographical area in Italy (16 Italian regions are 
represented) and include both big and smaller MS centres. All the neurologists had a long experience in 
treating MS lasting at least 5 years. 
 
The work lasted for about 18 months and was organized into four steps. 
 
The first step consisted in collecting existing documents of information and consent routinely used in 
different MS centres to inform patient about DMTs options and side effects. All available documents were 
then analysed by the medico-legal advisor who underlined criticisms and major flaws of the existing 
material and highlighted medico-legally relevant criteria that should be met in the organization of a new 
resource. In the second step, two plenary discussions were planned in order to review the medico-legal 
advisor criticisms on the available materials and, informed by these criticisms, to develop a structured 
template that could be used as a model for the new resource. In the third step, the whole cohort of 
participants was divided into small groups (2–4 members per group) to focus on the development of 
specific documents for individual DMTs. The fourth step consisted in two new plenary meetings for the 




In daily clinical practice, all MS centres participating in this project already used written material to 
support patient information and to acquire informed consent, when a second-line therapy or an off-label 
drug is prescribed. Eight out of 28 (29%) of the participating MS centres used written material to support 
patient information and to acquire informed consent when a first-line treatment has to be initiated. The 
analysed in-use documents appeared to be very heterogeneous among MS centres and sometimes lacking 
of key information (i.e. alter-natives to the proposed treatment or specific information about pregnancy 
or drug to drug interactions). The main criticisms of these documents underlined by the medicolegal 
advisor were: The language in which the current resources are written:  
• The information was conveyed in technical terms or jargon. 
• The structure of the documents, in which information about medications, indications, side effects 
and declaration of consent are not clearly separated in different sections, thus generating 
confusion. 
• The absence of a specific section on alternatives to the proposed treatment, their risks and 
benefits. 
The absence of a section, in which the risks and benefits of declining any treatment are stated. 
Informed by these criticisms, a standardized template for the construction of a new resource was 
developed. The new resource consisted of two different parts: an information sheet, specific for each 
drug, and a declaration of consent which was independent on the treatment proposed. Each information 
sheet includes six key information: (1) a statement on the diagnosis and prognosis of MS, (2) the 
indication of the proposed treatment, (3) the known risks and the expected side effects of the proposed 
treatment, (4) the effects of the pro-posed DMT on fertility, pregnancy and lactation, (5) the possible 
alternative treatments to the treatment proposed, their risks and benefits, as well as the risks and 
benefits of declining any treatment and (6) the planned monitoring, including the possibility of stopping 
or switching between treatments. 
The declaration of consent provides the possibility of a declaration of an impartial witness and includes 
the written expression of consent to use personal anonymized data for scientific purpose (Table 1). The 
collection and the exploitation of this data need the approval of the Ethical Local Committee and are 
under the responsibility of each single clinical centre where PWMS is followed in agreement with the 
European General Data Protection Regulation (GDPR), the guidelines of the Italian Data Protection 
Authority and the Italian legislation on consent. 
 
Table 1 Structure of the inter-centre shared template for information about DMTs and consent taking 
Part 1: information sheet 
1. What is MS? 
2. MS prognosis 
3. What is the “proposed DMT” (“active principle”) 
4. Why we suggest you to take that DMT to treat MS 
5. What are the most relevant side effects of the proposed DMT 
6. Effects of the proposed DMT on fertility, pregnancy and lactation 
7. Which are the possible alternative treatments 
8. Which are the risks of refusing or delaying treatment 
9. How to use the proposed treatments: administration and monitoring 
 
Part 2: declaration of consent 
1. Consent to be treated with the proposed DMT and to accept all monitoring procedures necessary 
for the specific treatment 
2. Privacy statements 
3. Consent to use, in aggregate mode, patient personal information for scientific purpose. 
4. Consent for eventual impartial witness (in case of subjects unable to read) 
 
After the small group work, 14 new information sheets, one for each available MS DMTs, and a declaration 
of consent, were obtained. After discussions and revisions all participant neurologists and the medico-
legal advisor reached consensus on the new documents. The new resource was submitted for the 
evaluation of MS study Group of the Italian Neurological Society and received the aegis of Italian 
Neurological Society (SIN). The new resource is now published on the SIN website (http://www.neuro.it) 
and is freely downloadable at http://www.rirems.it/consensi-dmts/. The resource is updated annually by 
the panel members on the basis of published evidence and available pharmacovigilance data. 
 
Discussion 
Available and in-use informative material about DMTs is very heterogeneous among Italian MS centres 
and sometimes lack of key information. To the best of our knowledge, this work is the first attempt to 
build a standardized, medico-legally super-vised, disease-specific inter-centres shared resource that is 
freely available and regularly updated in order to facilitate and support the information process of PWMS 
about DMTs. Clear and complete information facilitating patient’sunderstanding of treatment options is 
the basis for patient’s engagement and corrected informed consent taking [7, 8]. The use of standardized 
information written resource allows physicians to meet the minimal standard of information, to 
demonstrate that the process of information has occurred and to provide the PWMS with a memorandum 
of the discussed items that can be shared with hi significant others or primary care physician. 
Furthermore,the possibility to share the load of the regular update of the resource is a clear advantage for 
the MS community. 
Although developed as a standardized tool, this written information can be flexibly adapted to the 
individual communication setting and cannot replace the specific patient- physician interaction [8] aimed 
to shared decisions, respectful of patient’s needs and views. 
This work represents only the first step towards an improved shared decision process around DMTs in 
MS, but it has already produced impact since it has been adopted by the National Neurological Society. 
Future directions of this work will be the validation in clinical practice of this multicentre shared 
document with the stakeholders of the information process (i.e. PWMS, MS nurses, MS neurologists not 
participating to the construction of the resource); with this objective, a qualitative study is ongoing. 
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